vs
Side-by-side financial comparison of Senmiao Technology Ltd (AIHS) and IGC Pharma, Inc. (IGC). Click either name above to swap in a different company.
Senmiao Technology Ltd is the larger business by last-quarter revenue ($358.7K vs $191.0K, roughly 1.9× IGC Pharma, Inc.). Senmiao Technology Ltd runs the higher net margin — -289.2% vs -953.4%, a 664.2% gap on every dollar of revenue. On growth, IGC Pharma, Inc. posted the faster year-over-year revenue change (-53.6% vs -60.9%).
Senmiao Technology Ltd is a China-based automotive service provider that operates online used car trading platforms, offers auto financing referral services, and matches after-sales support for individual consumers and small auto dealers across domestic regional markets. Its core segments include transaction facilitation, financing consulting, and other value-added services for the domestic automotive circulation sector.
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
AIHS vs IGC — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $358.7K | $191.0K |
| Net Profit | $-1.0M | $-1.8M |
| Gross Margin | 13.8% | 51.8% |
| Operating Margin | -305.7% | -1517.8% |
| Net Margin | -289.2% | -953.4% |
| Revenue YoY | -60.9% | -53.6% |
| Net Profit YoY | -83.5% | -6.1% |
| EPS (diluted) | $-0.29 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $358.7K | — | ||
| Q3 25 | $906.5K | $191.0K | ||
| Q2 25 | $836.0K | $328.0K | ||
| Q1 25 | $809.6K | — | ||
| Q4 24 | $917.0K | $257.0K | ||
| Q3 24 | $742.3K | $412.0K | ||
| Q2 24 | $873.8K | $272.0K | ||
| Q1 24 | $-71.5K | $295.0K |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-648.7K | $-1.8M | ||
| Q2 25 | $-164.4K | $-1.6M | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $-565.3K | $-1.8M | ||
| Q3 24 | $-711.4K | $-1.7M | ||
| Q2 24 | $-673.4K | $-2.4M | ||
| Q1 24 | $-1.4M | $-2.9M |
| Q4 25 | 13.8% | — | ||
| Q3 25 | 30.2% | 51.8% | ||
| Q2 25 | 23.6% | 47.0% | ||
| Q1 25 | 48.7% | — | ||
| Q4 24 | 11.6% | 40.5% | ||
| Q3 24 | 13.1% | 48.1% | ||
| Q2 24 | 29.0% | 59.9% | ||
| Q1 24 | 176.1% | 58.0% |
| Q4 25 | -305.7% | — | ||
| Q3 25 | -83.6% | -1517.8% | ||
| Q2 25 | -73.1% | -580.8% | ||
| Q1 25 | -255.3% | — | ||
| Q4 24 | -44.8% | -730.7% | ||
| Q3 24 | -83.0% | -427.2% | ||
| Q2 24 | -88.6% | -880.9% | ||
| Q1 24 | 2115.7% | -735.6% |
| Q4 25 | -289.2% | — | ||
| Q3 25 | -71.6% | -953.4% | ||
| Q2 25 | -19.7% | -487.5% | ||
| Q1 25 | -219.3% | — | ||
| Q4 24 | -61.7% | -711.7% | ||
| Q3 24 | -95.8% | -416.7% | ||
| Q2 24 | -77.1% | -874.3% | ||
| Q1 24 | 1932.0% | -978.0% |
| Q4 25 | $-0.29 | — | ||
| Q3 25 | $-0.43 | $-0.02 | ||
| Q2 25 | $-0.15 | $-0.02 | ||
| Q1 25 | $1.51 | — | ||
| Q4 24 | $-0.54 | $-0.02 | ||
| Q3 24 | $-0.68 | $-0.02 | ||
| Q2 24 | $-0.64 | $-0.03 | ||
| Q1 24 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $397.3K | $8.1M |
| Total Assets | $5.7M | $9.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.5M | — | ||
| Q3 25 | $677.0K | $1.1M | ||
| Q2 25 | $867.8K | $454.0K | ||
| Q1 25 | $701.3K | — | ||
| Q4 24 | $949.2K | $470.0K | ||
| Q3 24 | $792.0K | $1.5M | ||
| Q2 24 | $748.9K | $1.8M | ||
| Q1 24 | $737.7K | $1.2M |
| Q4 25 | $397.3K | — | ||
| Q3 25 | $-3.1M | $8.1M | ||
| Q2 25 | $-2.6M | $6.1M | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $-1.2M | $6.3M | ||
| Q3 24 | $-459.2K | $7.4M | ||
| Q2 24 | $159.2K | $7.9M | ||
| Q1 24 | $894.9K | — |
| Q4 25 | $5.7M | — | ||
| Q3 25 | $4.7M | $9.7M | ||
| Q2 25 | $5.3M | $7.9M | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $7.9M | $9.1M | ||
| Q3 24 | $8.6M | $10.4M | ||
| Q2 24 | $9.2M | $10.6M | ||
| Q1 24 | $9.9M | $9.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-865.6K | $-2.1M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -1109.4% |
| Capex IntensityCapex / Revenue | — | 15.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-865.6K | — | ||
| Q3 25 | $-71.4K | $-2.1M | ||
| Q2 25 | $-321.2K | $-1.4M | ||
| Q1 25 | $-48.1K | — | ||
| Q4 24 | $356.1K | — | ||
| Q3 24 | $175.6K | $-996.0K | ||
| Q2 24 | $16.8K | $-1.8M | ||
| Q1 24 | $-247.5K | $-526.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.4M | ||
| Q1 25 | $-49.3K | — | ||
| Q4 24 | $355.3K | — | ||
| Q3 24 | $175.6K | $-1.0M | ||
| Q2 24 | $15.6K | $-1.8M | ||
| Q1 24 | $-275.8K | $-541.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | -1109.4% | ||
| Q2 25 | — | -431.4% | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | 38.8% | — | ||
| Q3 24 | 23.7% | -248.8% | ||
| Q2 24 | 1.8% | -658.1% | ||
| Q1 24 | 385.8% | -183.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 15.2% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | 7.0% | ||
| Q2 24 | 0.1% | 14.0% | ||
| Q1 24 | -39.6% | 5.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
